MedTrace Logo

Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence

NCT03108885 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2024-03-22

No results posted yet for this study

Summary

To prospectively collect blood and tumor tissue from esophageal cancer patients to identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence.

Conditions

  • Esophageal Neoplasm
  • Esophageal Neoplasms Malignancy Unspecified
  • Esophageal Neoplasms Malignant
  • Cancer of Esophagus
  • Cancer of the Esophagus
  • Esophageal Cancer
  • Esophagus Cancer
  • Neoplasm, Esophageal

Interventions

OTHER

Blood and Tissue Collection

Blood DNA will be isolated from plasma. Tumor DNA will be purified with a kit and amplified regions of 10 genes discovered to by mutated in whole exome sequencing.

Sponsors & Collaborators

Principal Investigators

  • Shanda Blackmon, MD, MPH · Mayo Clinic

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2020-05-25
Completion
2020-05-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03108885 on ClinicalTrials.gov